Related Experiment Videos
Addressing Barriers to Clozapine Underutilization: A National Effort
Deanna L Kelly1, Oliver Freudenreich1, MacKenzie A Sayer1
1Dr. Kelly and Ms. Sayer are with the Maryland Psychiatric Research Center, School of Medicine, and Dr. Love is with the School of Pharmacy, University of Maryland, Baltimore. Dr. Freudenreich is with the Schizophrenia Clinical and Research Program, Massachusetts General Hospital, Harvard University, Boston.
Psychiatric Services (Washington, D.C.)
|October 17, 2017
Summary
Clozapine is effective for refractory psychosis but underutilized due to barriers like prescriber knowledge and system unpreparedness. Addressing these issues is crucial for improving patient access and treatment management.
Area of Science:
- Psychiatry and Pharmaceutical Sciences
Background:
- Clozapine offers unique efficacy for treatment-resistant psychosis.
- Significant barriers hinder clozapine's real-world application and lead to underutilization in the US.
Purpose of the Study:
- To identify and address the multifaceted barriers impeding clozapine's use.
- To advocate for improved access and treatment management for patients requiring clozapine.
Main Methods:
- Convening a national expert work group under the National Association of State Mental Health Program Directors (NASMHPD).
- Monthly deliberations to develop and refine recommendations for overcoming identified barriers.
Main Results:
- Identified key barriers: prescriber knowledge gaps, negative attitudes, monitoring complexities, administrative hurdles, system unpreparedness, and policy/payer misapprehensions.
- Established a continuous work group to address these challenges.
Conclusions:
- Systemic and individual barriers significantly limit clozapine's accessibility.
- A collaborative effort involving practitioners, policymakers, and patient advocates is essential to enhance clozapine utilization and patient outcomes.